These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 35427491)

  • 1. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
    Whittles LK; Didelot X; White PJ
    Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.
    Régnier SA; Huels J
    Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study.
    Looker KJ; Booton R; Begum N; Beck E; Shen J; Turner KME; Christensen H
    BMC Public Health; 2023 Jan; 23(1):1. PubMed ID: 36624437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol.
    Thng C; Semchenko EA; Hughes I; O'Sullivan M; Seib KL
    BMC Public Health; 2023 Mar; 23(1):607. PubMed ID: 36997957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Ahoure M; Denehy E; Flood L; Marshall H
    J Infect; 2023 Aug; 87(2):95-102. PubMed ID: 37268223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H
    Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection.
    Nikitin D; Whittles LK; Imai-Eaton JW; White PJ
    J Infect Dis; 2024 Apr; ():. PubMed ID: 38630583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK.
    Ladhani SN; White PJ; Campbell H; Mandal S; Borrow R; Andrews N; Bhopal S; Saunders J; Mohammed H; Drisdale-Gordon L; Callan E; Sinka K; Folkard K; Fifer H; Ramsay ME
    Lancet Infect Dis; 2024 Sep; 24(9):e576-e583. PubMed ID: 38521080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study.
    Abara WE; Bernstein KT; Lewis FMT; Schillinger JA; Feemster K; Pathela P; Hariri S; Islam A; Eberhart M; Cheng I; Ternier A; Slutsker JS; Mbaeyi S; Madera R; Kirkcaldy RD
    Lancet Infect Dis; 2022 Jul; 22(7):1021-1029. PubMed ID: 35427490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Potential of Vaccination to Combat Antibiotic Resistance in Gonorrhea: A Modeling Analysis to Determine Preferred Product Characteristics.
    Whittles LK; White PJ; Didelot X
    Clin Infect Dis; 2020 Nov; 71(8):1912-1919. PubMed ID: 31905399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against
    Seib KL; Donovan B; Thng C; Lewis DA; McNulty A; Fairley CK; Yeung B; Jin F; Fraser D; Bavinton BR; Law M; Chen MY; Chow EPF; Whiley DM; Mackie B; Jennings MP; Jennison AV; Lahra MM; Grulich AE
    BMJ Open; 2024 Apr; 14(4):e081675. PubMed ID: 38626958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study.
    Petousis-Harris H; Paynter J; Morgan J; Saxton P; McArdle B; Goodyear-Smith F; Black S
    Lancet; 2017 Sep; 390(10102):1603-1610. PubMed ID: 28705462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model.
    Argante L; Abbing-Karahagopian V; Vadivelu K; Rappuoli R; Medini D
    BMC Infect Dis; 2021 Dec; 21(1):1244. PubMed ID: 34895161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
    de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
    Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
    Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
    Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study.
    Campbell H; Andrews N; Parikh SR; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME; Ladhani SN
    Lancet Child Adolesc Health; 2022 Feb; 6(2):96-105. PubMed ID: 34883094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.